Companies Dominating the Histone Deacetylase Inhibitors Market
- Acrotech Biopharma Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol Myers Squibb Co.
- Celleron Therapeutics Ltd.
- Novartis AG
- Midatech Pharma PLC
- REGENACY PHARMACEUTICALS, INC.
- Syndax Pharmaceuticals Inc.
- Viracta Therapeutics Inc.
- Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
- Cetya Therapeutics Inc.
- Italfarmaco SpA
- Vanda Pharmaceuticals Inc.
The market evolving its dynamics with the continuous participation in rigorous R&D cohorts by key players. They are heavily investing in advanced technologies to conduct clinical trials more efficiently and to mitigate related hurdles. Furthermore, the support from regulatory frameworks is escalating the pace of both domestic and international commercialization. For instance, in August 2021, Celgene Corporation attained accelerated approval from the FDA for its histone deacetylase (HDAC) inhibitor, Istodax (romidepsin). This drug is indicated to be used as a monotherapy for treating peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. Such key pioneers are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of histone deacetylase inhibitors is estimated at USD 1.44 billion.
The histone deacetylase inhibitors market size was over USD 1.35 billion in 2024 and is anticipated to cross USD 3.5 billion by 2037, growing at more than 7.6% CAGR during the forecast period i.e., between 2025-2037. Rising cases of cancer across the globe and growing research & development activities for the development of advanced drugs will drive the market growth.
North America industry is predicted to account for largest revenue share of 35% by 2037, impelled by rising investment in healthcare in the region.
The major players in the market are Novartis AG, Midatech Pharma PLC, REGENACY PHARMACEUTICALS, INC., Syndax Pharmaceuticals Inc., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., Cetya Therapeutics Inc., Tokyo Chemical Industry Co. Ltd., AstraZeneca Plc.
